Brief: FDA Grants Camurus Orphan Drug Designation For The Treatment Of Polycystic Liver Disease

Camurus AB

16/09/2021 10:04

Sept 16 (Reuters) - Camurus AB  CAMX.ST :
    * FDA GRANTS ORPHAN DRUG DESIGNATION IN THE US FOR CAM2029 FOR THE TREATMENT OF POLYCYSTIC
LIVER
DISEASE
    * FDA GRANTS ORPHAN DRUG DESIGNATION IN THE US FOR CAM2029 FOR THE TREATMENT OF POLYCYSTIC
LIVER
DISEASE
    * US FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED ORPHAN DRUG DESIGNATION (ODD) FOR
COMPANY'S
INVESTIGATIONAL MEDICINAL PRODUCT, OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029), FOR TREATMENT OF
AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE.

Source text for Eikon:  ID:nWkr4ZvQLR 
Further company coverage:  CAMX.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))